Abstracts tagged "Biologics"

Abstract Number: 2449 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tocilizumab (TCZ) Monotherapy with Tumor Necrosis Factor Inhibitors (TNFi) in Combination with Varying Doses of Methotrexate (MTX) in Patients with Rheumatoid Arthritis
Leslie R Harrold¹, George W. Reed¹, Jennie Best², Steve Zlotnick², Gioia Persuitte³ and Joel Kremer⁴, ¹University of Massachusetts Medical School, Worcester, MA, ²Genentech, Inc., South San Francisco, CA, ³Corrona, LLC, Southborough, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Clinical studies have shown that the efficacy of TCZ monotherapy (TCZ mono) is superior to that of TNFi monotherapy and comparable to that of…
Abstract Number: 2871 • 2017 ACR/ARHP Annual Meeting
Anti-RA33 (hnRNP-A2/B1) Autoantibodies Are Associated with the Therapeutic Response to Methotrexate and Anti-TNF Treatment in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Paul Studenic¹, Farideh Alasti², Daniel Aletaha³, Josef S. Smolen¹ and Günter Steiner², ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Besides the determination of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), anti-RA33 antibodies (which are directed to the nuclear antigen hnRNP-A2/B1) could be…
Abstract Number: 595 • 2017 ACR/ARHP Annual Meeting
Improved Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Abatacept: Results from a Phase III Trial
Vibeke Strand¹, E Alemao², T Lehman², A Johnsen², S Banerjee², HA Ahmad² and Philip J Mease³, ¹Stanford University, Palo Alto, CA, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: In the Phase III ASTRAEA study (NCT01860976), abatacept (ABA) significantly increased ACR20 responses, alleviating musculoskeletal symptoms in patients (pts) with active psoriatic arthritis (PsA).1…
Abstract Number: 1041 • 2017 ACR/ARHP Annual Meeting
Real-World Utilization of Biosimilars for Management of Rheumatoid Arthritis (RA) in the US
Janna Radtchenko, Yolaine Smith, Jonathan Kish and Bruce Feinberg, Specialty Solutions, Cardinal Health, Dallas, TX
Background/Purpose: A biosimilar product is a biological product highly similar to another FDA-approved biological product, reference product, and has no clinically meaningful differences in safety…
Abstract Number: 1525 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Patterns Among Patients with Psoriatic Arthritis Initiating Subcutaneously Administered Biologics: Descriptive Analyses from a US Claims Database
Kurt R. Oelke¹, Rahul Garg², Peter Hur³, Olivier Chambenoit³, Amar Q. Majjhoo⁴, Stephani Gray⁵, Kate Higgins⁵ and Jacqueline B. Palmer³, ¹Rheumatic Disease Center, Glendale, WI, ²PRO Unlimited, Inc, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Shores Rheumatology, St. Clair Shores, MI, ⁵Truven Health Analytics, Cambridge, MA
Background/Purpose: To better understand the real-world efficacy of biologics for the treatment of psoriatic arthritis (PsA), there is a need to evaluate the persistence and…
Abstract Number: 2460 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Joel Kremer¹, William F C Rigby², Nora Singer³, Christine Birchwood⁴, Darcy Gill⁴, William Reiss⁴, Jennie Best⁴, Jinglan Pei⁴ and Margaret Michalska⁴, ¹Albany Medical College, Albany, NY, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) often receive methotrexate (MTX) in combination with biologics; however, MTX may be discontinued due to intolerance or to reduce…
Abstract Number: 2878 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
Atul A. Deodhar¹, Alice B Gottlieb², Wolf-Henning Boehncke³, Bin Dong⁴, Yuhua Wang⁴, Yanli Zhuang⁴, William Barchuk⁵, Xie L. Xu⁵ and Elizabeth Hsia⁴, ¹Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, ²Department of Dermatology, New York Medical College, Valhalla, NY, ³Geneva University Hospital and University of Geneva, Geneva, Switzerland, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, San Diego, CA
Background/Purpose: Evaluate efficacy and safety of guselkumab (GUS) in patients (pts) with active psoriatic arthritis (PsA) over 56 weeks (wks). Methods: Pts w/active PsA (defined…
Abstract Number: 597 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors
Arthur Kavanaugh¹, Helena Marzo-Ortega², Ronald Vender³, Julie Birt⁴, David Adams⁴, Olivier Benichou⁴, Chen-Yen Lin⁴ and Peter Nash⁵, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, ³Dermatrials Research, Inc., Hamilton, ON, Canada, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. Up to 24 weeks, IXE was superior to placebo (PBO) in improving…
Abstract Number: 1044 • 2017 ACR/ARHP Annual Meeting
Medical Care Costs Associated with Rheumatoid Arthritis in the US: A Meta-Analysis
Andrew Hresko¹, Tzu-Chieh Lin² and Daniel H. Solomon³, ¹Tufts Medical School, Boston, MA, ²Health Outcomes, Amgen, Thousand Oaks, CA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a morbid, mortal, and costly condition without a cure. Treatments for RA have expanded over the last two decades…
Abstract Number: 1528 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Rapid and Sustained Pain Relief in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels and Correlated with Improvement in Fatigue
Atul A. Deodhar¹, Philip G. Conaghan², Tore K Kvien³, Vibeke Strand⁴, Lawrence Rasouliyan⁵, Brian Porter⁶, Steffen Jugl⁷ and Kunal Gandhi⁶, ¹Oregon Health & Science University, Portland, OR, ²University of Leeds, Leeds, United Kingdom, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Stanford University School of Medicine, Palo Alto, CA, ⁵RTI Health Solutions, Barcelona, Spain, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab has demonstrated sustained efficacy in patients (pts) with active AS.1,2 We investigated improvement in pain and fatigue scores from baseline (BL) through Week…
Abstract Number: 2461 • 2017 ACR/ARHP Annual Meeting
Rituximab Is Effective in the Treatment of Rheumatoid Arthritis Irrespective of Body Mass Index; Up to 48 Weeks Results from Phase 3 Study
Dae-Hyun Yoo¹, Won Park², Chang-Hee Suh³, Seung-Cheol Shim⁴, Sang-Joon Lee⁵, Yun Ju Bae⁵, Chan Park⁵ and Noo Ri Han⁵, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Medicine/Rheumatology, Inha University Hospital, Incheon, Korea, Republic of (South), ³Ajou University School of Medicine, Suwon, Korea, Republic of (South), ⁴Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ⁵CELLTRION, Inc., Incheon, Korea, Republic of (South)
Background/Purpose: High body mass index (BMI) is known to be associated with inadequate clinical response to anti-TNF agents in RA patients.1 However, there are limited…
Abstract Number: 2879 • 2017 ACR/ARHP Annual Meeting
Switching from Adalimumab to Chs-1420: A Randomized, Double-Blind Global Clinical Trial in Patients with Psoriasis and Psoriatic Arthritis
Jennifer Hodge, Hong Tang, Paula O'Connor and Barbara Finck, Coherus BioSciences, Inc., Redwood City, CA
Background/Purpose: CHS-1420 is a proposed biosimilar to adalimumab. A phase 3, randomized, double-blind, multicenter study evaluated the equivalence of CHS-1420 to adalimumab in patients with…
Abstract Number: 605 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Exhibits a Favorable Safety Profile during 24 Weeks of Treatment in Subjects with Active Psoriatic Arthritis: Integrated Safety Analysis of Two Randomized, Placebo Controlled, Phase III Clinical Trials
Philip J Mease¹, Gerd R. Burmester², Susan Moriarty³, Olivier Benichou³, Wen Xu³ and Peter Nash⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ³Eli Lilly and Company, Indianapolis, IN, ⁴University of Queensland, Brisbane, Australia
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets IL-17A. The objective of this analysis is to report the integrated safety of…
Abstract Number: 1092 • 2017 ACR/ARHP Annual Meeting
The Ottawa Biologics Safety and Screening Tool
Chrisanna Dobrowolski¹, Ines Midzic², Denise Boone², Anne McCarthy³, Doug Smith², John Thomson², Sheryl Izzi⁴ and Susan Humphrey-Murto², ¹Internal Medicine, The Ottawa Hospital - University of Ottawa, Ottawa, ON, Canada, ²Division of Rheumatology, Department of Medicine, The Ottawa Hospital - University of Ottawa, Ottawa, ON, Canada, ³Division of Infectious Diseases, Department of Medicine, The Ottawa Hospital - University of Ottawa, Ottawa, ON, Canada, ⁴Division of Endocrinology, Department of Medicine, The Ottawa Hospital - University of Ottawa, Ottawa, ON, Canada
Background/Purpose : A large proportion of patients with rheumatologic diseases are now being treated with biologic therapies. Estimates of the use of biologics in patients…
Abstract Number: 1529 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Consistent Safety over Long-Term Exposure (up to 3 years) in Patients with Active Ankylosing Spondylitis: Pooled Analysis of Three Phase 3 Trials
Atul A. Deodhar¹, Xenofon Baraliakos², Helena Marzo-Ortega³, Joachim Sieper⁴, Mats Andersson⁵, Brian Porter⁶ and Todd Fox⁵, ¹Oregon Health & Science University, Portland, OR, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³NIHR LBRC, LTHT and LIRMM, UoL, Leeds, United Kingdom, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Secukinumab has demonstrated a consistent and reliable safety profile in three Phase 3 studies in ankylosing spondylitis (AS): MEASURE 1 (NCT01358175), MEASURE 2 (NCT01649375),…

« Previous Page
1
…
7
8
9
10
11
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.